Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa

Journal of AIDS and Clinical Research

Volumn 2, Issue 2, 2011, Pages

  El Khatib, Ziad ^a,b   DeLong, Allison K ^c   Katzenstein, David ^d   Ekstrom, Anna Mia ^a   Ledwaba, Johanna ^b   Mohapi, Lerato ^e   Laher, Fatima ^e   Petzold, Max ^f   Morris, Lynn ^b   Kantor, Rami ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c BROWN UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^g BROWN UNIVERSITY   (United States)

Author keywords

ART experienced; Drug resistance; First line ART; HIV 1; Mutations; NNRTI; South Africa; Subtype C

Indexed keywords

EID: 84857147376     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000117     Document Type: Article

References (43)

1. Bangsberg DR, Kroetz DL, Deeks SG (2007) Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 4: 65-72.
2. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10:155-166.
3. Charalambous SA, Grant JD, Pemba L, Chaisson R, Kruger P, et al. (2007) Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 19: 34-41.
4. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to Nonnucleoside Reverse-Transcriptase Inhibitorbased therapy. Clin Infect Dis 48: 462-472.
5. Cozzi-Lepri A, Phillips AN, Ruiz L, Clote B, Loveday C, et al. (2007) Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 21:721-732.
6. Datay MI, Boulle A, Mant D, Yudkin P (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 54: 489-495.
7. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797-800.
8. Deshpande A, Jeannot AC, Schrive MH, Wittkop L, Pinson P, et al. (2010) Analysis of RT sequences of subtype C HIV-type 1 isolates from Indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. AIDS Res Hum Retrovirus 26: 343-350.
9. El-Khatib Z (2004) Questionnaire design and data entry in EpiData Guideline. Division of Clinical Cancer Epidemiology-Karolinska Institutet.
10. El-Khatib ZA, Ekstrom M, Laher F, Karstaedt AS, Petzold M, et al. (2009) Medical review-South African adherence and virologic evaluation (MR. SAVE) tool, 1.0 ed.
11. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a crosssectional study in Soweto, South Africa. AIDS 24: 1679-1687.
12. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
13. HIV Stanford Database (2010) HIV Stanford Database, vol. 2010, Palo Alto, California, USA.
14. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, et al. (2009) Viremia, resuppression, and time to resistance in Human Immunodeficiency Virus (HIV) Subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 49:1928-1935.
15. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, et al. (2009) The public health approach to identify antiretroviral therapy failure: highlevel nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
16. Johnson, VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2009) Update of the drug resistance mutations in HIV-1. Top HIV Med 17:138-145.
17. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, et al. (2007) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 356: 135-147.
18. Kantor R., Shafer RW, Follansbee S, Taylor J, Shilane D, et al. (2004) Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18: 1503-1511.
19. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, et al. (2009) Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J Acquir Immune Defic Syndr 50: 9-18.
20. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, et al. (2008) Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. PLoS Med 5:e148.
21. Kumarasamy NV, Madhavan K Venkatesh S, Saravanan R, Kantor P, et al. (2009) High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 49: 306-309.
22. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, et al. (2004) Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351: 217-228.
23. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, et al. (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 370: 39-48.
24. Ledwaba J, Hunt G, Rakgotho M, El-Khatib Z, Singh S, et al. (2009) HIV-1 transmitted drug resistance surveillance in three provinces in South Africa during 2002-2007. Antivir Ther 14: A182.
25. Lockman S (2008) Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. Curr Opin HIV AIDS 3:166-72.
26. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, et al. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135-147.
27. Maartens G, Venter F, Meintjes G, Cohen K (2008) Southern African HIV clinicians society-Guidelines for antiretroviral therapy in adults. 03-Oct.-2009.
28. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46:1589-1597.
29. Martinson N, Mohapi L, Bakos D, Gray GE, McIntyre JA, et al. (2009) Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa. J Acquir Immune Defic Syndr 50: 327-330.
30. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-574.
31. Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, et al. (2007) The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retrovirus 23:868-878.
32. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12: 83-88.
33. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg JA, et al. (2009) HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 14: 523-531.
34. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, et al. (2007) Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 13: 101-107.
35. Pillay V, Pillay C, Kantor R, Venter F, Levin L, et al. (2008) HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retrovirus 24:1449-1454.
36. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, et al. (2007) Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 45: 1492-1498.
37. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS (2007) High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retrovirus 23:1303-1308.
38. StataCorp LP (2008) Stata/SE 10.1 College Station, TX 77845 USA.
39. Steingrover R, Pogany K, Fernandez Garcia E, Jurriaans S, Brinkman K, et al. (2008) HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22:1583-1588.
40. The R project for statistical computing (2010) The R project for statistical computing
41. Uy J, Armon C, Buchacz K, Wood K, Brooks JT (2009) Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 51: 450-453.
42. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W (2009) Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 480-484.
43. World Health Organization (WHO) UNAIDS, and UNICEF (2009) Towards universal access-Scaling up priority HIV/AIDS interventions in the health sector.